Withaferin A activates TRIM16 for its anti-cancer activity in melanoma. by Nagy, Z et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:19724  | https://doi.org/10.1038/s41598-020-76722-x
www.nature.com/scientificreports
Withaferin A activates TRIM16 
for its anti‑cancer activity 
in melanoma
Zsuzsanna Nagy1,2,6, Belamy B. Cheung1,2,3,6*, Wing Tsang1, Owen Tan1, Mika Herath1, 
Olivia C. Ciampa1, Fatima Shadma1, Daniel R. Carter1,2,4 & Glenn M. Marshall1,5*
Although selective BRAF inhibitors and novel immunotherapies have improved short‑term treatment 
responses in metastatic melanoma patients, acquired resistance to these therapeutics still represent 
a major challenge in clinical practice. In this study, we evaluated the efficacy of Withaferin A (WFA), 
derived from the medicinal plant Withania Somnifera, as a novel therapeutic agent for the treatment 
of melanoma. WFA showed selective toxicity to melanoma cells compared to non‑malignant cells. 
WFA induced apoptosis, significantly reduced cell proliferation and inhibited migration of melanoma 
cells. We identified that repression of the tumour suppressor TRIM16 diminished WFA cytotoxicity, 
suggesting that TRIM16 was in part responsible for the cytotoxic effects of WFA in melanoma cells. 
Together our data indicates that WFA has potent cytopathic effects on melanoma cells through 
TRIM16, suggesting a potential therapeutic application of WFA in the disease.
Malignant melanoma is the deadliest cutaneous neoplasm. Acquired drug resistance frequently develops after 
a period of objective tumor response, justifying the need for novel  therapies1,2. Withaferin A (WFA), a steroidal 
lactone extracted from Withania somnifera, has been described as a potential anti-cancer drug both in vivo 
and in vitro3,4 through its diverse anti-tumour properties and low cytotoxicity to non-malignant cells. WFA is 
a promising therapeutic agent for a broad range of cancers, however its mechanism of action is understudied. 
Recent research has demonstrated a number of possible mechanisms of action for WFA, such as direct inhibition 
of the intermediate filament  vimentin5,6. Inhibition of vimentin reduces formation of metastasis in pre-clinical 
models of breast cancer, osteosarcoma and lung cancer, melanoma and hepatocellular  carcinoma7–11. We have 
 reported12 that the expression of TRIM16 (tripartite motif 16) is significantly reduced during normal skin transi-
tion to squamous cell carcinoma. We have also shown that TRIM16 acts as a tumour suppressor and reduces cell 
motility via down-regulation of vimentin  expression12. We have also shown that high TRIM16 protein expres-
sion is associated with favourable outcome in melanoma patients with stage III  disease13. Moreover, suppression 
of TRIM16 expression increased migration of normal human epidermal melanocytes, while overexpression 
of TRIM16 reduced melanoma cell migration and  proliferation13. The above detailed evidence suggested that 
increased TRIM16 expression is a potential molecular target for the treatment of melanoma.
Results
WFA has increased cytotoxicity for melanoma cells compared with fibroblast cell lines. To 
determine whether WFA had selective cytotoxicity to melanoma cells over non-malignant cells, WFA was 
screened at a range (0–5 μM) of concentrations for its effects on cell viability (Fig. 1A) against five melanoma cell 
lines (MelCV, MelJD, G3601, A375 and MM200) compared with normal human lung fibroblasts (MRC-5 and 
WI-38). WFA demonstrated marked single agent activity against three of the five melanoma cell lines (MelJD, 
MelCV, G361) and reduced toxicity toward normal fibroblasts (Fig. 1A). Comparison of overall IC50s of the 
melanoma cell lines and fibroblast cells (Fig. 1B) showed a significant increase in cytotoxicity for melanoma cells. 
WFA also exerted a concentration-dependent anti-proliferative effect (Fig. 1C) measured by the BrdU cell prolif-
eration assay in the case of MelJD and MelCV melanoma cells when compared to fibroblasts. Anti-proliferative 
actions developed at much lower WFA concentrations (Fig. 1C). To determine the effect of WFA treatment on 
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cell death, mitochondrial membrane potential (one of the earliest markers of apoptosis) was measured using a 
MITOPROBE DILC1(5) Assay. WFA treatment significantly decreased the mitochodrial membrane potential of 
MelJD and MelCV cells in a concentration-dependent manner (Fig. 1D), while WI-38 and MRC-5 normal fibro-
blasts were less sensitive to the treatment and very marginal. In order to further investigate early apoptotic and 
necrotic processes during treatment, we further assessed the effects of WFA on melanoma cells by measuring 
Annexin-V positivity (Fig. 1E and Supplementary Fig. 1) of MelJD and MelCV cells treated with increasing WFA 
concentrations (0–5 µM). Importantly, we found that in line with our cell viability data, WFA induced apoptotic 
Figure 1.  WFA has selective toxicity to melanoma cells compared with fibroblast cell lines. (A), A panel of 
melanoma (MelJD, MelCV, G361, A375 and MM200) cells and normal fibroblasts (WI-38, MRC-5) were 
treated with increasing concentrations (0–5 μM) of Withaferin A (WFA) for 48 h and cell viability was 
measured using the Alamar Blue assay. (B), Average IC50 for WFA-treated melanoma cell lines and normal 
fibroblasts. Melanoma cell lines (MelJD and MelCV) and normal fibroblasts (WI-38, and MRC-5) were treated 
with increasing concentrations (0–5 μM) of WFA for 48 h, followed by (C), BrdU cell proliferation assay (D), 
MITOPROBE  DILC1(5) measurements. (E), Flow cytometry results of MelJD and MelCV cells treated with 
increasing concentrations of WFA, then stained with Annexin-V-FITC/7AAD. Results are mean ± SEM, data 
was normalized to vehicle control treatment group.
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:19724  | https://doi.org/10.1038/s41598-020-76722-x
www.nature.com/scientificreports/
and necrotic events in MelJD and MelCV cells in a concentration-dependent manner (Fig. 1E). To investigate 
the effect of WFA treatment on cell migration, we examined the motility of MelJD and MelCV cells in a trans-
well assay. As shown in Fig. 2, MelJD and MelCV cells treated with WFA demonstrated slower cell migration 
compared to the vehicle treated control cells.
WFA induces TRIM16 protein expression in melanoma cells. To determine whether TRIM16 is 
responsible for the anti-cancer effects of WFA in melanoma cells, MelJD and MelCV cells were treated with 
increasing concentrations of WFA and changes in TRIM16 protein and mRNA expression was analyzed by 
western blot and RT-qPCR. WFA treatment increased TRIM16 protein expression in both MelJD and MelCV 
cells in a dose-dependent manner (Fig. 3A, B). TRIM16 mRNA expression levels also increased (Fig. 3C) in 
both MelJD and MelCV cells during WFA treatment, suggesting that WFA induces TRIM16 expression at a 
transcriptional level.
WFA is partially dependent on TRIM16 for its cytotoxic activity. To evaluate whether induction 
of TRIM16 expression was essential for WFA to exert its effect on melanoma cell survival, we silenced TRIM16 
gene expression using two TRIM16-specific siRNAs (Fig. 4A and Supplementary Fig. 2) in MelJD and MelCV 
melanoma cells, followed by treatment with WFA. As expected, WFA treatment significantly reduced cell via-
bility of both MelJD and MelCV cells (Fig. 4B), when compared to DMSO treated siControl (Vehicle) cells. 
Conversely, we found that knockdown of TRIM16 using TRIM16-specific siRNAs blocked the reduction of 
cell viability induced by WFA treatment in both MelJD and MelCV cells (Fig. 4B) when compared to DMSO 
treated siControl (Vehicle) cells. BrdU cell proliferation (Fig. 4C) and colony formation assays (Fig. 4D, E) also 
showed that while WFA significantly reduced both short and long-term proliferation of both MelJD and MelCV 
cells, knockdown of TRIM16 rescued the cells from the effects of WFA. Furthermore, WFA treatment signifi-
cantly decreased the survival of MelJD and MelCV cells as measured by their mitochodrial membrane potential 
(Fig. 4F), however, cells transfected with TRIM16 specific siRNAs were less sensitive to WFA treatment. We fur-
ther assessed the effects of TRIM16 expression on necrotic events (SYTOX Green accumulation assay) induced 
by WFA. We found that in line with our cell viability data, WFA induced necrosis in WFA treated melanoma 
cells (Fig. 4G), however, knockdown of TRIM16 rescued the cells from the cytotoxic effects induced by WFA.
Discussion
Although, kinase inhibitors and immunotherapies using checkpoint inhibitors have greatly improved survival of 
melanoma patients with advanced disease, treatment failure still represents a major clinical  issue1,2. Hence, there 
is an urgent need to introduce novel therapeutics for the treatment of melanoma. The therapeutic effects of WFA 
in regulating cell survival, migration, angiogenesis, proliferation and metastasis in many types of  cancers14 has 
drawn more attention toward WFA as an anti-cancer compound. WFA induces mitochondrial dysfunction as 
well as apoptosis in leukaemia  cells15, melanoma  cells16 and breast cancer  cells17. WFA was also found to prevent 
angiogenesis by binding to vimentin  filaments5 and  nestin18. Although these studies have shown that WFA is 
an effective anti-cancer compound for a variety of cancers, the molecular mechanism of WFA’s drug action in 
melanoma is not fully understood. The objective of the present study was to further investigate the anti-cancer 
potential of WFA against human melanoma and to decipher the molecular mechanisms involved.
Although the effect of WFA on melanoma cell  viability16 and  proliferation19,20 has been investigated before, in 
this study, we conducted a thorough investigation using a wide range of melanoma cell lines, as well as normal 
fibroblasts to investigate the therapeutic window and concentration range for WFA to be administered without 
the risk of adverse side-effects. Previous studies have shown that WFA administration inhibits in vivo growth of 
a variety of tumor  xenografts17,19,21 including uveal  melanoma19, as well the sensitizing effect of WFA of B16F1 
Figure 2.  WFA treatment decreases melanoma cell migration. MelJD and MelCV cells treated with indicated 
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melanoma cells to  radiotherapy22. Further investigation using preclinical animal models to test WFA efficacy for 
melanoma is a natural extension to our current study.
G2/M cell cycle arrest and apoptosis induction following treatment with WFA has been reported for 
 melanoma16 and uveal  melanoma19. In melanoma cell lines, the apoptotic process triggered by WFA involved 
the mitochondrial pathway and was associated with Bax mitochondrial translocation, cytochrome-c release, 
transmembrane potential changes, and caspase 9 and caspase 3 activation. WFA cytotoxicity may also require 
Figure 3.  WFA treatment induces TRIM16 protein expression. (A), Western blot images of TRIM16 and 
GAPDH protein expression in MelJD and MelCV cells treated with WFA at increasing concentrations. The full-
length blots are presented in the Supplementary Fig. 3A. (B), The level of TRIM16 protein expression measured 
by densitometry quantification. (C), RT-qPCR analysis of TRIM16 mRNA expression in MelJD and MelCV cells 
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early reactive oxygen species (ROS)  production16. Consistent with this data, both melanoma cell lines in our 
study had a concentration-dependent increase in apoptosis. Interestingly, MelJD cells (BRAFWT) were more 
sensitive to the cytotoxic effect of WFA compared to MelCV cells, suggesting that BRAF mutation status might 
regulate sensitivity to WFA. A more intensive investigation is required to understand the link between WFA 
sensitivity and BRAF mutational status both in vitro and in vivo.
Here, we have shown that WFA treatment induced TRIM16 mRNA expression in melanoma cell lines and that 
TRIM16 was required to induce maximal cytotoxic effect. We found that MelCV melanoma cells were less sensi-
tive to WFA treatment in comparison to MelJD cells. Interestingly, MelCV cells showed a lower basal TRIM16 
expression compared to the MelJD  cells13. We hypothesize that MelCV cells may be intrinsically less sensitive 
to WFA treatment due to pre-existing lower basal of TRIM16 and that the apoptotic action of TRIM16 may be 
suppressed by other means in these cells. The mechanism by which TRIM16 expression is lost in melanoma 
cells is currently unknown. Previous data indicated multiple mechanisms in neuroblastoma, including promoter 
methylation and reduced protein  stability23, similar dysregulation may occur in melanoma. We showed that with 
increasing WFA concentration, the induction of TRIM16 mRNA expression was only mild, suggesting it is also 
possible that WFA can act by other regulatory mechanisms such as post-translational modifications that increase 
the stability or inhibit proteosomal degradation of TRIM16. The latter hypothesis was supported by research that 
shows WFA can inhibit the proteasome, the site of TRIM16  degradation12,24.
WFA treatment effectively reduced the growth of 4T1 mouse mammary tumor  xenografts11. Growth inhibi-
tion was also accompanied by degradation of  vimentin11. WFA was also found to prevent angiogenesis by binding 
to the intermediate F-actin and vimetin  filaments5 and  nestin18. It has been previously described that TRIM16 
bound directly to cytoplasmic  vimentin23. We hypothesize that the inhibition of this interaction is necessary 
for the action of WFA on melanoma cells. Stage III melanoma patients with lymph node metastases have high 
TRIM16 expression with a longer median survival (59 months) compared to patients with low TRIM16 expres-
sion (16 months)23, therefore we investigated the effect of WFA on melanoma cell migration. Consistent with 
studies conducted in breast cancer cell  lines11, our migration assay results demonstrated that WFA inhibited 
melanoma cell migration. Therefore, we suggest that WFA treatment and upregulation of TRIM16 expression 
could be a potential method to prevent disease progression and serve as maintenance therapy for Stage II mela-
noma patients.
Despite promising in vitro data summarized in this article, several steps are still necessary to introduce WFA 
for prevention and/or therapy of melanoma. Studies on WFA efficacy in vivo would further validate this com-
pound as a candidate for therapeutic development. Second, more intensive investigation is required to understand 
the link between WFA sensitivity and BRAF mutational status. Last, it is unknown whether TRIM16 reactivation 
by WFA potentiate another targeted anti-melanoma therapy.
Materials and methods
Cell culture. Melanoma cell lines, MelJD, MelCV and MM200 were kindly gifted from Professor Xu Dong 
Zhang at the University of Newcastle (Newcastle, NSW, Australia). Melanoma cell line G361 and A375 were pur-
chased from ATCC. All melanoma cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(LIFE TECHNOLOGIES Australia, VIC, Australia) with 5% fetal calf serum (FCS) (LIFE TECHNOLOGIES). 
MRC-5 and WI-38 normal human fibroblasts were purchased from ATCC and grown in alpha-minimum essen-
tial media (MEM) (LIFE TECHNOLOGIES) supplemented with 10% heat inactivated FCS. All cells were freshly 
thawed from initial seeds, cultured at 37 °C/5%  CO2 in a humidifier incubator for not more than 2 months.
siRNA transfection. For siRNA mediated knock-down, the indicated cell lines were transfected with 
20  nM of custom designed siRNA duplex oligos (TRIM16 siRNA#1: (5′AGT AAT TCA CCA TGC AGG TTT-3′ 
and TRIM16 siRNA#2: (5′TCT CCC TCC TGC ATT TGT GTT-3′) synthesized by QIAGEN, Australia. Non-tar-
geting pool siRNA was used as siControl and purchased from DHARMACON, Australia. Cells were transfected 
between 24 to 72 h depending on the experimental requirements. Transfections were performed using Lipo-
fectamine 2000 (LIFE TECHNOLOGIES) following the manufacturer’s protocol.
Pharmacological growth assays. Pharmacological growth inhibition assays were performed using 
2 × 104 melanoma cells per well and 8 × 103 fibroblasts cells per well in 96- well microplates. When applicable, 
cells were transfected with either TRIM16 siRNA#1, TRIM16 siRNA#2 or Control siRNA. 24 h after transfec-
tion, serial dilutions of Whitaferin A (WFA) was added to the cells (0–5 µM). Cells were incubated with vehicle 
control (DMSO) or WFA for 48 h followed by cell viability, cell proliferation, cell death as well as colony forma-
tion assays.
Cell viability assay. The number of viable cells was determined by using the Alamar Blue assay (LIFE 
TECHNOLOGIES) according to the manufacturer’s protocol. Signals were quantitated on a VICTOR MUL-
TILABEL COUNTER (PERKINELMER, Australia) at an excitation wavelength of 560  nm and an emission 
wavelength of 590 nm.
Cell proliferation assay. Cell proliferation was measured using BrdU ELISA kit (ROCHE, Australia) 
according to manufacturer’s instructions. Cells were grown in medium containing 5 μg/ml BrdU for 4 h (MelJD 
and MelCV) or 6 h (WI-38 and MRC-5) and fixed in 4% paraformaldehyde. DNA was denatured, and cells were 
permeabilized in 2 N HCl with 0.5% Triton X-100 (SIGMA, Australia) and then blocked with 5% BSA in PBS. 
Anti-BrdU was added following the manufacturer’s protocol. After washing with 5% BSA in PBS, the cells were 
incubated with Alexa-Fluor-594-conjugated anti-mouse-IgG (MOLECULAR PROBES, MA, USA). Changes in 
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Figure 4.  Knock-down of TRIM16 protects melanoma cells against WFA. (A), Western blot analysis of TRIM16 
expression in MelJD and MelCV cells following TRIM16 knock-down. GAPDH was used as internal control. The 
full-length blots are presented in the Supplementary Fig. 3B. MelJD and MelCV cells were transfected with control 
siRNA (siControl) or TRIM16 siRNAs (siTRIM16) for 24 h, then treated with WFA for additional 48 h followed by 
(B), Alamar Blue cell viability and (C), and BrdU cell proliferation measurements. Results are mean ± SEM, differences 
in cell viability and proliferation were compared to the vehicle (DMSO) treated siRNA control cells. (D), MelJD and 
MelCV cells expressing TRIM16 siRNAs (siTRIM16) or control siRNA (siControl) were seeded for colony formation 
assay and treated with indictaed concentrations of WFA for 72 h then allowed for colonies to form for 10 days, 
followed by crystal violet staining. (E), Quantification of colony formation assay based on crystal violet absorbance 
(590 nm). Differences in colony formation were compared to the vehicle treated control siRNA. MelJD and MelCV 
cells were transfected with control siRNA (siControl) or TRIM16 siRNAs (siTRIM16) for 24 h, then treated with 
WFA for additional 48 h followed by (F,) MITOPROBE  DILC1(5) and (G), SYTOX Green measurements. Results are 
mean ± SEM, differences in cell viability and proliferation were compared to the vehicle control siRNA control cells.
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cell proliferation were calculated from the absorbance readings at 370 nm (490 nm reference wavelength) on the 
Benchmark Plus microplate reader (BIO-RAD, Australia).
Colony formation. For the colony-formation assay, 250 MelJD and MelCV cells were seeded in 6-cm2 plates 
and kept under WFA treatment for 72 h, and grown for 10 days to allow colonies to form. Colonies were fixed 
and stained with crystal violet solution (SIGMA) then washed with water to remove unincorporated stain. Cells 
were photographed and colony formation was quantified from crystal violet absorbance readings at 590 nm on 
the Benchmark Plus microplate reader (BIO-RAD).
Determination of cell death. Mitochondrial membrane potential of cells was determined using a MITO-
PROBE  DIIC1(5) Assay Kit (LIFE TECHNOLOGIES). 2 × 104 melanoma cells per well and 8 × 103 fibroblast 
cells were cultured in 96-well plates and treated with WFA for 48 h. After treatment, cells were incubated with 
 DILC1(5) working solution (50 nM/well) for 30 min, and the fluorescence of  DILC1(5) was measured at 630-nm 
excitation and 670-nm emission wavelengths using VICTOR Multilabel Counter (PERKINELMER).
In addition, apoptosis was also assessed by measuring phosphatidylserine translocation with FITC-conjugated 
Annexin-V using cell apoptosis kit I (BD BIOSCIENCE, San Jose, CA, USA). Briefly, MelJD and MelCV cells 
were treated with increasing concentrations of WFA (0–5 µM), then double stained with 7AAD and Annexin-
V-FITC, following the manufacturer’s protocol. Untreated cells with no stain were used as a negative control. 
Fluorescence intensity was measured by the FACS-CANTO Flow Cytometer (BD BIOSCIENCE).
The cytotoxic effects of WFA treatment were determined by SYTOX Green staining (LIFE TECHNOLO-
GIES). Melanoma cells (2 × 104 cells per well) were cultured in 96-well plates and treated with WFA for 48 h. 
Supernatants were then discarded, and the cells were incubated with SYTOX Green working solution (30 nM/
well) for 30 min. The fluorescence of SYTOX Green was measured at 490-nm excitation and 520-nm emission 
wavelengths using VICTOR Multilabel counter (PERKINELMER).
Cell migration assay. MelJD and MelCV cells were serum starved prior to seeding into a trans-well 
insert (BD BIOSCIENCES) along with WFA. Trans-well inserts were placed in a companion plate with 5% FCS 
media as chemo-attractant, plates were then incubated for an additional 18 h. After incubation, cells were fixed 
with methanol, and stained with May-Grunwald (SIGMA-ALDIRCH, Australia) and Giemsa Stain (SIGMA-
ALDRICH). Data was generated by counting cells under microscope (OLYMPUS, × 20 objective). Migration 
index was calculated by dividing migrated cell with total number of cells in wells.
Western blot analysis. Cell pellets were lysed with Radioimmunoprecipitation assay (RIPA) buffer freshly 
supplemented with protease inhibitor cocktail (SIGMA-ALDRICH). Protein lysate was standardized using the 
BCA protein quantitation assay kit as per manufacturer’s instructions (THERMO SCIENTIFIC, IL, USA), and 
20–40 µg whole protein lysates were resolved on either 10.5% or 10–14% Tris–HCl Criterion gels (BIO-RAD, 
Gladesville, NSW, Australia). Nitrocellulose membranes (GE HEALTHCARE, Rydalmere, NSW, Australia) 
were blocked with 5% (wt/vol) nonfat dry milk in Tris-buffered saline with Tween-20 (20 mM Tris–HCl (pH 
7.6), 137 mM NaCl, 0.1% Tween-20), then incubated overnight at 4 °C with the following primary antibodies: 
TRIM16 (1:1000; BETHYL LABORATORIES, TX, USA) and GAPDH antibody (1:1000; SANTA CRUZ BIO-
TECHNOLOGIES, Texas, USA). Appropriate horseradish peroxidase conjugated secondary antibodies (1:3000; 
SANTA CRUZ BIOTECHNOLOGIES and MERCK MILLIPORE, Australia) were diluted in Tris-buffered saline 
with 0.1% Tween-20 and membranes were probed on room temperature for 2 h. Immunoblots were visualized 
with SUPER SIGNAL WEST PICO Chemiluminescence reagents (THERMO SCIENTIFIC PIERCE, Australia). 
Densitometry of protein expression was measured using Image Lab software (https ://www.bio-rad.com/en-au/
produ ct/image -lab-softw are?ID=KRE6P 5E8Z) (BIO-RAD) and each protein expression band was normalized 
to GAPDH loading control.
RNA isolation and quantitative real‑time PCR (RT‑qPCR). Total RNA was extracted using the 
PURELINK RNA kit (LIFE TECHNOLOGIES) according to the manufacturer’s protocol. 1  μg total RNA 
was reverse-transcribed using the TETRO cDNA synthesis kit (BIOLINE, Australia). 1 μL of purified cDNA 
(0.1–1  μg) was added to a reaction mix containing, 2.5  μL 10× PCR buffer, 1.5 μL 25  mM MgCl, 2.5 μL of 
10 mM dNTPs, 0.5 μL GOLD TAQ (INVITROGEN) and 1 μL of each of forward and reverse TRIM 16 primers 
(10  nM): Forward CAG GCT CCA GGC TAA CCA AAAG and Reverse TCC TCT AAG AAG GGC ATC ACA TTG . 
Gene expression was verified using Power SYBR GREEN MIX (APPLIED BIOSYSTEMS, LIFE TECHNOLO-
GIES) PERFORMED ON ABI7500 THERMO-CYCLER (APPLIED BIOSYSTEMS, LIFE TECHNOLOGIES) 
with a standard protocol. Differential gene expression was measured using the log2∆∆Ct analysis. All mRNA 
expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Statistical analysis. Data were analysed with Prism 7 software (GRAPHPAD) and results are presented 
as the mean ± SEM. All statistics were based on continuous variables. For single comparisons, differences were 
determined by using a two-tailed, unpaired Student’s t-test with a confidence interval (CI) of 95%. For multiple 
comparison one-way ANOVA was used. P ≤ 0.05 was denoted as statistically significant. Drug dose–response 
curves were analysed with a nonlinear regression curve fit model. The p values are as indicated on images. Analy-
ses were not performed in a blinded manner.
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Data availability
All data generated or analyzed during this study are included in this published article. Uncropped and unpro-
cessed immunoblot scans for all main figure immunoblots are provided as Supplementary Information.
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